2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117970
    MMPI-1154 1382722-47-5 99.76%
    MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively.
    MMPI-1154
  • HY-121457
    9-Nitrooleate 875685-44-2 99.4%
    9-Nitrooleate, a nitro fatty acid, is a nitro derivative of Oleic acid (HY-N1446). 9-Nitrooleate has potential for use in vascular disease research.
    9-Nitrooleate
  • HY-122094
    Steppogenin 56486-94-3 99.49%
    Steppogenin is a potent inhibitor of HIF-1α and DLL4, with IC50 values of 0.56 and 8.46 μM, respectively. Steppogenin can be sued for the research of angiogenic diseases, such as those involving solid tumors.
    Steppogenin
  • HY-122365
    Inositol nicotinate 6556-11-2 98.05%
    Inositol nicotinate (Hexanicit) has vasodilating effects and can be used in research on peripheral arterial disease, showing efficacy when taken orally. Inositol nicotinate does not significantly improve triglyceride levels in mice induced by biphenyl esters.
    Inositol nicotinate
  • HY-122830
    DD-03-171 2366132-45-6 98.72%
    DD-03-171 is a PROTAC BTK degrader. DD-03-171 inhibits mantle cell lymphoma (MCL) cell proliferation (IC50 = 5.1 nM) and prolongs the survival of mice bearing a lymphoma PDX model by degrading BTK, IKFZ1, and IKFZ3. DD-03-171 also inhibits platelet function and thrombosis. (Pink: BTK ligand 9 (HY-168292); Black: linker (HY-28875); Blue: Thalidomide-NH-CH2-COOH (HY-131717)).
    DD-03-171
  • HY-125748
    CBM-301940 902146-11-6 99.4%
    CBM-301940 (compound 5) is an orally active malonate CoA decarboxylase (MCD) inhibitor with IC50 value of 23 nM. CBM-301940 can be used in the study of cardiovascular diseases.
    CBM-301940
  • HY-130335
    Encainide 66778-36-7 99.92%
    Encainide (MJ9067) is an antiarrhythmic agent with class IC activity. Encainide blocks voltage-dependent potassium channels. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research.
    Encainide
  • HY-132828
    Odatroltide 1639303-73-3
    Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities.
    Odatroltide
  • HY-135746
    OR-1896 220246-81-1 99.04%
    OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation.
    OR-1896
  • HY-135774
    6-Hydroxybenzbromarone 152831-00-0 99.96%
    6-Hydroxybenzbromarone is the major metabolite of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound. 6-Hydroxybenzbromarone is a protein Eyes Absent 3 (EYA3) inhibitor with an IC50 value of 21.5 μM. 6-Hydroxybenzbromarone is an anti-angiogenic agent, has strong inhibitory effects on cell migration, tubulogenesis, and angiogenic sprouting.
    6-Hydroxybenzbromarone
  • HY-136300
    PHD-1-IN-1 2009343-14-8 99.21%
    PHD-1-IN-1 is an orally active and potent HIF prolylhydroxylase domain-1 (PHD-1) inhibitor with an IC50 of 0.034 μM. PHD-1-IN-1 has a unique monodentate binding interaction with the active site Fe2+ ion and induces the formation of an "Arg367-out" pocket.
    PHD-1-IN-1
  • HY-148327
    AK-IN-1 378775-98-5 99.21%
    AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures.
    AK-IN-1
  • HY-148505
    5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite) 1197033-17-2 99.17%
    5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is a potent nucleic acid analog. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite blongs to modified antisense oligonucleotide. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite allows the formation of a specific conformation of the furanose ring of the oligonucleotide through the introduction of a cEt modification, enhancing the ability to hybridize to complementary RNA. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is mainly used in the research of regulation of gene expression related to metabolic diseases, cardiovascular diseases, cancers and the development of antisense compounds.
    5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite)
  • HY-155773
    VU534 923509-20-0 98.10%
    VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
    VU534
  • HY-162345
    CK-963 2851991-63-2 99.23%
    CK-963 is an activator for cardiac troponin (cTnC) with Ki of 11.5 μM. CK-963 exhibits activity in enhancing cardiac contractility in Sprague-Dawley rats.
    CK-963
  • HY-163348
    FXIIa-IN-4 98.87%
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant.
    FXIIa-IN-4
  • HY-168894
    CT-1 99.90%
    CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment.
    CT-1
  • HY-173162
    GPV0057 86383-89-3 99.20%
    GPV0057 (Compound 5d) is a selective and potent P-glycoprotein (P-gp) inhibitor. GPV0057 is also a selective potassium channel Kir2.1 activator. GPV0057 competitively binds to the substrate-binding site of P-gp, inhibiting ATP-dependent drug efflux to reverse multidrug resistance in tumor cells. GPV0057 can also stabilizes the open state of Kir2.1 and promotes potassium ion influx. GPV0057 is promising for research of tumors with high P-gp expression, Kir2.1-deficient diseases such as heart failure and Andersen-Tawil Syndrome.
    GPV0057
  • HY-173572
    SKLB-11A 433953-86-7 99.40%
    SKLB-11A is a selective, orally active and allosteric SIRT3 (sirtuin 3) agonist with a Kd value of 4.7 μM. SKLB-11A is highly selective for other members of the SIRT family. SKLB-11A activates autophagy-related signaling pathways, prevents mitochondrial dysfunction, improves cardiac function in Doxorubicin (HY-15142A)-induced cardiotoxicity and myocardial ischemia/reperfusion models.
    SKLB-11A
  • HY-176860
    NEK7 degrader-1 3069891-91-1 99.94%
    NEK7 degrader-1 is a NEK7 molecular glue degrader with a DC50 of 9  nM. NEK7 degrader-1 dose-dependently inhibits caspase-1 activity and IL-Ιβ release in macrophages in response to NLRP3 inflammasome activation. NEK7 degrader-1 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research.
    NEK7 degrader-1
Cat. No. Product Name / Synonyms Application Reactivity